Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (otvara se novi prozor)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Izvor‎: Cancer 2013;119(21):3784-7.

Indeks‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (otvara se novi prozor)

Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? (otvara se novi prozor)

Chakrabarti S, Varma S, Singh S, Kumari S

Izvor‎: Eur J Haematol 1998;60(5):313-4.

Indeks‎: PubMed 9654162

DOI‎: 10.1111/j.1600-0609.1998.tb01046.x

https://www.ncbi.nlm.nih.gov/pubmed/9654162 (otvara se novi prozor)

The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia. (otvara se novi prozor)

Delaney M, Matthews DC, Gernsheimer TB

Izvor‎: Pediatr Blood Cancer 2017;64(12):e26641.

Indeks‎: PubMed 28544698

DOI‎: 10.1002/pbc.26641

https://www.ncbi.nlm.nih.gov/pubmed/28544698 (otvara se novi prozor)

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. (otvara se novi prozor)

Kaye JD, Smith EA, Kirsch AJ, Cerwinka WH, Elmore JM

Izvor‎: J Urol 2010;184(3):1152-7.

Indeks‎: PubMed 20650477

DOI‎: 10.1016/j.juro.2010.05.020

https://www.ncbi.nlm.nih.gov/pubmed/20650477 (otvara se novi prozor)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (otvara se novi prozor)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Izvor‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indeks‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (otvara se novi prozor)

Pediatric off-label use of recombinant factor VIIa. (otvara se novi prozor)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Izvor‎: Pediatrics 2009;123(3):1066-72.

Indeks‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (otvara se novi prozor)

Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. (otvara se novi prozor)

Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A.

Izvor‎: Indian J Pediatr 2011;78(8):961-8.

Indeks‎: PubMed 21328080

DOI‎: 10.1007/s12098-011-0364-6

https://www.ncbi.nlm.nih.gov/pubmed/21328080 (otvara se novi prozor)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (otvara se novi prozor)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Izvor‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indeks‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (otvara se novi prozor)

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. (otvara se novi prozor)

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL

Izvor‎: Pediatr Blood Cancer 2016;63(10):1822-8.

Indeks‎: PubMed 27232114

DOI‎: 10.1002/pbc.26082

https://www.ncbi.nlm.nih.gov/pubmed/27232114 (otvara se novi prozor)

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. (otvara se novi prozor)

Das P, Carcao M, Hitzler J

Izvor‎: Pediatr Blood Cancer 2006;47(2):206-9.

Indeks‎: PubMed 16007583

DOI‎: 10.1002/pbc.20467

https://www.ncbi.nlm.nih.gov/pubmed/16007583 (otvara se novi prozor)

A comprehensive review of rFVIIa use in a tertiary care pediatric center. (otvara se novi prozor)

Heller M, Lau W, Pazmino-Canizares J, Brandão LR, Carcao M

Izvor‎: Pediatr Blood Cancer 2008;50(5):1013-7.

Indeks‎: PubMed 17960639

DOI‎: 10.1002/pbc.21375

https://www.ncbi.nlm.nih.gov/pubmed/17960639 (otvara se novi prozor)

Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. (otvara se novi prozor)

Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O

Izvor‎: Blood Coagul Fibrinolysis 2005;16(2):145-7.

Indeks‎: PubMed 15741803

DOI‎: 10.1097/01.mbc.0000161569.66764.70

https://www.ncbi.nlm.nih.gov/pubmed/15741803 (otvara se novi prozor)

Off-label use of recombinant factor VIIa in pediatric patients. (otvara se novi prozor)

McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee

Izvor‎: Pediatrics 2012;129(6):e1533-40.

Indeks‎: PubMed 22641758

DOI‎: 10.1542/peds.2011-2561

https://www.ncbi.nlm.nih.gov/pubmed/22641758 (otvara se novi prozor)

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) registry (2004-2008). (otvara se novi prozor)

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators

Izvor‎: Pediatr Blood Cancer 2013;60(7):1178-83.

Indeks‎: PubMed 23335449

DOI‎: 10.1002/pbc.24472

https://www.ncbi.nlm.nih.gov/pubmed/23335449 (otvara se novi prozor)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (otvara se novi prozor)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Izvor‎: Med Oncol 2010;27(1):16-9.

Indeks‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (otvara se novi prozor)

Successful treatment of acute lymphoblastic leukemia with l-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. (otvara se novi prozor)

Ucar C, Caliskan U

Izvor‎: Pediatr Hematol Oncol 2006;23(4):339-45.

Indeks‎: PubMed 16621776

DOI‎: 10.1080/08880010600631987

https://www.ncbi.nlm.nih.gov/pubmed/16621776 (otvara se novi prozor)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (otvara se novi prozor)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Izvor‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Indeks‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (otvara se novi prozor)

The use of DDAVP in children with bleeding disorders. (otvara se novi prozor)

Ben-Ami T, Revel-Vilk S

Izvor‎: Pediatr Blood Cancer 2013;60 Suppl 1:S41-3.

Indeks‎: PubMed 23109357

DOI‎: 10.1002/pbc.24335

https://www.ncbi.nlm.nih.gov/pubmed/23109357 (otvara se novi prozor)

Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). (otvara se novi prozor)

Kobrinsky NL, Tulloch H

Izvor‎: J Pediatr 1988;112(6):993-6.

Indeks‎: PubMed 3373409

DOI‎: 10.1016/s0022-3476(88)80234-8

https://www.ncbi.nlm.nih.gov/pubmed/3373409 (otvara se novi prozor)

The use of Tachosil as hemostatic sealant in nephron sparing surgery for Wilms tumor: preliminary observations. (otvara se novi prozor)

Mele E, Ceccanti S, Schiavetti A, Bosco S, Masselli G, Cozzi DA

Izvor‎: J Pediatr Surg 2013;48(3):689-94.

Indeks‎: PubMed 23480936

DOI‎: 10.1016/j.jpedsurg.2013.01.019

https://www.ncbi.nlm.nih.gov/pubmed/23480936 (otvara se novi prozor)